Investigation of endothelial toxicity after allogeneic haematopoietic stem cell transplantatio

Not Applicable

Completed

• Conditions: toxicity of allogeneic haemopoietic cell transplant regimens; Blood - Haematological diseases

• Registration Number: ACTRN12616000709448
• Lead Sponsor: Fiona Stanley Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-27
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1.Completed work-up and planned to proceed with allogeneic HSCT at Fiona Stanley Hospital
2.Has had sufficient work-up to enable haematopoietic cell transplantation-specific comorbidity index (HCT-CI) to be calculated (minimum: history and examination, lung function studies, assessment of cardiac ejection fraction)
3.Will receive one of the following conditioning regimens: busulfan + cyclophosphamide, TBI + cyclophosphamide or fludarabine + melphalan
4.Will receive GVHD prophylaxis with a calcineurin inhibitor (cyclosporine or tacrolimus) and short course methotrexate, with or without ATG
5.Provides informed consent to participate in the study

Exclusion Criteria

1.Incomplete pre-transplant work-up (see inclusion criteria 2 above)
2.Will receive a conditioning regimen or GVHD prophylaxis regimen other than those specified in the inclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified